Chair, Xenome
| Role | Organisation | Sources |
|---|---|---|
| Chair | Xenome | GBS Ventures (17 Jan 2012), GBS Ventures (11 Aug 2009) |
| Director (former) | Chemgenex | GBS Ventures (11 Aug 2009), GBS Ventures (29 Jun 2009) |
Stories naming Dr Julie Cherrington. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
A January 2012 post on GBS Ventures' news page announces Julie Cherrington as the new board chair of Xenome, tasked with steering the company through a pivotal stage; details sit in an attached document.
Xenome appointed Dr Julie Cherrington, president of San Diego biopharmaceutical Phenomix and a Progen board member, as an independent director of the drug developer, effective 1 August 2009.
ASX-listed drug developer ChemGenex will quit NASDAQ and SEC reporting to cut compliance costs, and three directors step down in July while staying on as advisers.